万泰生物涨2.05%，成交额2.79亿元，主力资金净流入945.90万元

Core Viewpoint - Wantaibio's stock has shown volatility with a recent increase, but the company has faced significant revenue and profit declines in the first half of 2025, indicating potential challenges ahead [1][2]. Company Overview - Wantaibio, established on April 24, 1991, and listed on April 29, 2020, is based in Beijing and specializes in the research, production, and sales of in vitro diagnostic reagents, instruments, and vaccines [1]. - The company's main revenue sources are diagnostic reagents (67.06%), vaccines (20.36%), diagnostic instruments (4.98%), agency products (4.97%), other (1.88%), and active ingredients (0.76%) [1]. Financial Performance - For the first half of 2025, Wantaibio reported a revenue of 844 million yuan, a year-on-year decrease of 38.25%, and a net profit attributable to shareholders of -144 million yuan, a decline of 155.30% [2]. - The company has distributed a total of 1.541 billion yuan in dividends since its A-share listing, with 1.311 billion yuan distributed over the past three years [3]. Shareholder Information - As of June 30, 2025, Wantaibio had 38,400 shareholders, an increase of 24% from the previous period, with an average of 32,958 circulating shares per shareholder, down 19.36% [2]. - The top ten circulating shareholders include Hong Kong Central Clearing Limited, which increased its holdings by 5.1508 million shares to 22.7544 million shares [3].